Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03257722
Title Pembrolizumab + Idelalisib for Lung Cancer Study
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Zhonglin Hao
Indications

lung non-small cell carcinoma

Therapies

Idelalisib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.